# US 2012/0253032 A1 · Novel cationic lipids with short lipid chains for oligonucleotide delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253032 A1
- Document ID: US20120253032A1
- Status: Published application
- Kind: A1
- Application number: 13/500,733
- Filed: 2010-09-20
- Published: 2012-10-04
- Earliest claimed: 2009-10-08
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Mark Cameron; Jennifer R. Davis; Weimin Wang
- Web page: https://patentgrep.com/patent/US20120253032A1

## CPC

- C07J 41/0055: {the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- C07J 43/003: {not condensed}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The instant invention provides for novel cationic lipids with short lipid chains that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo while decreasing inflammatory toxicities.

## Claims

### Claim 1

A cationic lipid of Formula A which is:
wherein:
p is 1 to 8;
R1 and R2 are independently selected from H, (C1-C10)alkyl, heterocyclyl, and a polyamine, wherein said heterocyclyl or polyamine is optionally substituted with one to three substituents selected from R3, or R1 and R2 can be taken together with the nitrogen to which they are attached to form a monocyclic heterocycle with 4-7 members optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic heterocycle optionally substituted with one to three substituents selected from R3;
R3 is independently selected from: halogen, OR4, SR4, CN, CO2R4, CON(R4)2;
R4 is independently selected from: H, (C1-C10)alkyl and aryl; and
Y is a (C4-C8)alkyl, (C4-C8)perfluoroalkyl, or a (C4-C8)alkenyl;
or any pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 2 (depends on 1)

A cationic lipid of Formula A according to claim 1, wherein:
p is 1 to 8;
is selected from:
n is 1 to 10; and
Y is a (C4-C8)alkyl, (C4-C8)perfluoroalkyl, or a (C4-C8)alkenyl;
or any pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 3 (depends on 1)

A cationic lipid of Formula A according to claim 1 which is selected from:
(2S)-2-{4-[(3β)-cholest-5-en-3-yloxy]butoxy}-N,N-dimethyl-3-(octyloxy)propan-1-amine;
(2R)-2-{4-[(3β)-cholest-5-en-3-yloxy]butoxy}-N,N-dimethyl-3-(octyloxy)propan-1-amine;
(2R)-2-({6-[(3β)-cholest-5-en-3-yloxy]hexyl}oxy)-N,N-dimethyl-3-(octyloxy)propan-1-amine;
(2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-(octyloxy)propan-1-amine;
1-[(2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-3-(octyloxy)propyl]guanidine;
1-[(2R)-2-{4-[(3β)-cholest-5-en-3-yloxy]butoxy}-3-(octyloxy)propyl]guanidine;
(3β)-3-(4-{[(2R)-1-(octyloxy)-3-(pyrrolidinyl-1-yl)propan-2-yl]oxy}butoxy)cholest-5-ene; and
(3β)-3-[(8-{[(2S)-1-(octyloxy)-3-(pyrrolidinyl-1-yl)propan-2-yl]oxy}octyl)oxy]cholest-5-ene
or any pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 4 (depends on 1)

The use of a cationic lipid according to claim 1 for the preparation of lipid nanoparticles.

### Claim 5 (depends on 1)

The use of a cationic lipid according to claim 1 as a component in a lipid nanoparticle for the delivery of oligonucleotides.

### Claim 6 (depends on 5)

The use according to claim 5 wherein the oligonucleotides are siRNA or miRNA.

### Claim 7 (depends on 5)

The use according to claim 5 wherein the oligonucleotides are siRNA.
